Neurocognitive Assessment CNSL and LGG
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorDana-Farber Cancer Institute
About this trial
This study is to determine whether self-administered digital cognitive tests can serve as accurate and reliable alternatives to established neuropsychological tests for evaluating cognitive functioning in participants with primary central nervous system lymphoma and low-grade gliomas.
Eligibility criteria
Qualifiers
Histopathologically confirmed newly diagnosed primary CNS diffuse large B-cell lymphoma (DLBCL) OR
Histopathologically confirmed IDH-M low grade glioma diagnosis in the past 12 months who have not started tumor directed therapy (if applicable).
Age ≥ 18 years.
Ability to consent to study.
Disqualifiers
Patients who have severe visual impairment that cannot be corrected with glasses to read regular sized print.
Patients who have known psychiatric or substance abuse disorders that would interfere with their cooperation in completing the requirements of the study.
Trial design
Treatments tested in this trial
- Digital Cognitive Assessment (TestMyBrain and Mobile Toolbox)
- Traditional Neuropsychological Testing
- Quality of Life and Mood Questionnaires
- Brain MRI (Standard of Care)
Treatment groups
36 Participants
are divided into 1 treatment groupLocations
Sponsors and collaborators
Source ClinicalTrials.gov